A daring timeline for AI-driven drug targets

The dawn of AI-driven medicine is upon us, and we're only a few years away from drug targets identified by machine learning, according to some experts.

“I would predict that within the next two to three years we’ll have examples of [drug] targets … discovered through machine learning methods that unravel biology that wasn’t appreciated before,” said Dr. Hal Barron, chief scientific officer of GlaxoSmithKline.

It’ll take much longer, of course, to translate those targets to the clinic. Biopharma is an industry that loves getting timeline predictions. That doesn't mean, of course, that those predictions come true.